Finding safer drug combinations for treating relapsed sarcoma in children
Official title: Identifying non-cardiotoxic drug combinations for patients with relapsed sarcoma
Funded at Seattle Children's Hospital · NIH-11037898 · Data updated 2026-11-12
This study is looking for safe drug combinations to help treat children with relapsed sarcoma while making sure they don’t harm the heart, using special models to test the treatments before trying them in kids.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Children's Hospital NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | February 16, 2024 |
| Project end | January 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $230,127 |
| NIH project number | 5R21CA280139-02 |
| Project ID | NIH-11037898 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children and young adults with relapsed sarcoma who are at risk of cardiotoxicity from standard treatments.
✕Less likely to help
Patients with sarcoma who are not experiencing relapse or those who are not at risk for cardiotoxicity may not benefit from this research.
What this research studies
This research aims to identify drug combinations that can effectively treat relapsed sarcoma in children without causing heart damage. By using advanced models, including mouse xenografts and zebrafish, the team will evaluate the cardiotoxic effects of these combinations before they are tested in patients. The goal is to develop safer treatment options that minimize the risk of heart complications while still targeting the cancer effectively.
Why it matters
Potential benefit: If successful, this research could lead to safer treatment options for children with relapsed sarcoma, reducing the risk of heart damage associated with current therapies.
How similar studies have gone: Other research has shown promise in developing safer cancer therapies, but this specific approach combining zebrafish and mouse models for cardiotoxicity assessment is relatively novel.
Where this research is happening
-
Seattle Children's Hospital
Seattle, United States Active
Researchers
- Principal investigator: Lawlor, Elizabeth R — Seattle Children's Hospital
- Study coordinator: Lawlor, Elizabeth R
Related research
Other NIH-funded projects on the same topics.
-
Testing new therapies for pediatric and young adult sarcoma, kidney, and liver cancers
Researchers are testing new drugs and smart combinations in models of pediatric cancers to help guide future treatments for kids and young adults.
-
Precision 3D Imaging to Monitor Kaposi Sarcoma (KS) with SkinScan3D
A new portable 3D imaging tool called SkinScan3D will help doctors measure KS skin lesions more accurately and quickly, especially in people living with HIV.
-
Precision 3D Imaging to Track Kaposi Sarcoma (KS) with SkinScan3D
A new 3D imaging tool called SkinScan3D helps doctors monitor Kaposi sarcoma lesions more accurately and quickly, especially in settings with high KS burden like East Africa and in U.S. clinics with HIV patients.
-
Rapid, bedside KS diagnosis in Africa with KS-COMPLETE
A fast, point-of-care test using skin biopsies to diagnose Kaposi’s sarcoma in sub-Saharan Africa, helping patients get results in about an hour.
-
Kaposi Sarcoma care and research in Africa during ART era
A collaborative program to better understand and improve diagnosis, treatment, and prevention of Kaposi sarcoma for people living with HIV in Zambia and Tanzania.
-
Kaposi Sarcoma in Africa: ART Era Research Network
A collaborative program in Africa and the United States will study Kaposi sarcoma in people living with HIV on ART to improve diagnosis, treatment, and prevention.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.